Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04242095 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects

StatusRecruiting
PhaseNot specified
Started2020-03-12
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 17, 2026 (before its estimated October 1, 2026 completion). Its status may not reflect the trial's current state.

Amendment history

The 50 most recent of 52 record versions are listed below. See every version on ClinicalTrials.gov ↗

2026-09-01
Study Status, Contacts/Locations v51
Enrollment increased: 240 → 2240 participants
Study sitescontacts updated at 5 of 625 sites
2026-08-04
Study Status, Contacts/Locations v50
Study sites625 entries, revised
Washington Health Englewood Hospital BJC Outpatientand Medical Center at Sunset Hills
2026-07-01
Study Status, Contacts/Locations v49
Study sites626→625
2026-06-01
Study Status, Contacts/Locations v48
Study sites626 entries, revised
CommonSpirit Saint Anthony Hospital Saint Michael Cancer Center Saint Joseph Medical Center Hematology and Oncology - Silverdale
2026-05-07
Study Status, Contacts/Locations v47
Study sites626 entries, revised
OptumCareWashington Cancer Care at Seven HillsHospital
Show 45 earlier versions
2026-04-06
Study Status, Contacts/Locations v46
Study sites625→626
2026-03-02
Study Status, Contacts/Locations v45
Study sitesdetails revised at 1 of 625 sites
2026-02-03
Study Status, Contacts/Locations v44
Study sitesdetails revised at 3 of 625 sites
2026-01-06
Study Status, Contacts/Locations v43
Study sites623→625
2025-12-08
Study Status, Contacts/Locations v42
Study sites622→623
2025-11-04
Study Status, Contacts/Locations v41
Study sites622 entries, revised
GenesisCareCancer USACare Northwest - LasSpokane VegasSouth GenesisCareCancer USACare Northwest-North Fort ApacheSpokane
2025-10-07
Study Status, Contacts/Locations v40
Study sites621→622
2025-09-05
Study Status, Contacts/Locations v39
Study sites620→621
2025-06-24
Study Status, Contacts/Locations v38
Study sites610→620
2025-03-28
Study Identification, Study Status, Oversight, Contacts/Locations, IPDSharing v37
Study sites604→610
Study titlerevised
Collection of Research Data and Samples fromFrom Patients Who Experience Immunotherapy Side Effects
2025-01-14
Study Identification, Study Status, Oversight, Contacts/Locations, IPDSharing v36
Primary completion date2025-10-01→2026-10-01
Completion date2025-10-01→2026-10-01
Start date2020-01-31→2020-03-12
Study sitesdetails revised at 485 of 604 sites
Study titlerevised
Collection of Research Data and Samples Fromfrom Patients Who Experience Immunotherapy Side Effects
2024-12-24
Study Status, Contacts/Locations v35
Study sites601→604
2024-10-24
Study Status, Contacts/Locations v34
Study sites595→601
2024-08-01
Study Status, Contacts/Locations v33
Study sites574→595
2024-05-22
Study Status, Contacts/Locations v32
Study sites573→574
2024-04-08
Study Status, Contacts/Locations v31
Study sites570→573
2024-02-19
Study Status, Contacts/Locations v30
Study sites566→570
2023-10-30
Study Status, Contacts/Locations v29
Study sites563→566
2023-08-30
Study Status, Contacts/Locations v28
Study sites546→563
2023-04-03
Study Status, Contacts/Locations v27
Study sites519→546
2023-02-06
Study Status v26
Primary completion date2022-10→2025-10-01
Completion date2025-02→2025-10-01
2022-09-25
Study Status, Contacts/Locations v25
Study sites519 entries, revised
MedicalMission OncologyCancer and HematologyBlood Associates- Laurel SeattleFHCC CancerSouth CareLake AllianceUnion
2022-08-02
Study Status, Contacts/Locations v24
Study sitesdetails revised at 6 of 519 sites
2022-07-15
Study Status, Contacts/Locations v23
Study sites517→519
2022-06-03
Study Status, Contacts/Locations v22
Study sites514→517
2022-04-18
Study Status, Contacts/Locations v21
Study sites513→514
2022-03-22
Study Status, Contacts/Locations v20
Study sites506→513
2021-11-11
Study Status, Contacts/Locations v19
Study sites505→506
2021-10-11
Study Status, Contacts/Locations v18
Study sites504→505
2021-08-16
Study Status, Contacts/Locations v17
Study sites502→504
2021-07-19
Study Status, Contacts/Locations v16
Study sites502 entries, revised
Loyola CenterMedicine forHomer Cancer Care and ResearchGlen
2021-06-09
Study Status, Contacts/Locations v15
Study sites492→502
2021-04-16
Study Status, Study Description, Eligibility, Contacts/Locations v14
Eligibility criteria+214 characters
Inclusion Criteria: MustReceived havea receivedregimen containing one or more IOimmuno-oncology therapeutics Must have experienced one or more of the following: One or more serious (gradeGrade 3-54) AEs that are likely immune-related One or more Grade 2 dermatologic or rheumatologic AEs that are likely immune-related Diagnosis of a rare infection, e.g., fungal or mycobacterial, after starting IO treatment ** Note: Diagnosis of SARS-CoV-2 (COVID-19) is excluded Hyperprogression. Image submission for patients experiencing [...] contact the study chair and submit images for central review Has not previo [...]
Study descriptionrevised
[...] O) therapeutics who experience one or more serious (grade 3-54) immune-related adverse events (irAEs), rare infections or [...]
Study sites492 entries, revised
OptumCare Cancer Care at OakeyCharleston
2021-03-05
Study Status, Contacts/Locations v13
Study sites491→492
2021-02-05
Study Status, Contacts/Locations v12
Study sites488→491
2021-01-08
Study Status, Contacts/Locations v11
Study sites484→488
2020-12-08
Study Status, Contacts/Locations v10
Study sites483→484
2020-11-10
Study Status, Contacts/Locations v9
Study sites461→483
2020-10-08
Study Status, Contacts/Locations v8
Study sites449→461
2020-09-03
Study Status, Contacts/Locations v7
Study sites433→449
2020-07-22
Study Status, Contacts/Locations v6
Study sites381→433
2020-06-03
Study Status, Contacts/Locations v5
Study sites366→381
2020-05-06
Study Status, Contacts/Locations v4
Study sites302→366
2020-04-09
Study Status, Contacts/Locations v3
Study sites192→302
2020-03-04
Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2020-02→confirmed 2020-01-31
Study sites0→192
This study collects research data and samples from patients who experience immunotherapy side effects to store for use in future research studies. Studying research data and samples from patients who experience immunotherapy side effects may help researchers better understand how to predict, prevent, and treat these side effects.
Trial Details
NCT Number NCT04242095
Lead Sponsor Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI)
Conditions Hematopoietic and Lymphoid Cell Neoplasm, Immune System Disorder, Malignant Solid Neoplasm
Enrollment 2,240 participants
Start Date 2020-03-12
Primary Completion 2026-10-01 (estimated)
Study Completion 2026-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-09-17